Striatal AMPA Receptor Binding Is Unaltered in the MPTP-Lesioned Macaque Model of Parkinson's Disease and Dyskinesia

Authors: Silverdale M.A.; Crossman A.R.; Brotchie J.M.

Source: Experimental Neurology, Volume 174, Number 1, March 2002 , pp. 21-28(8)

Buy & download fulltext article:

Price: $52.63 plus tax (Refund Policy)

Abstract:

Long-term levodopa or dopamine agonist treatment in the MPTP-lesioned primate model of Parkinson's disease elicits dyskinesia, which is phenotypically similar to levodopa-induced dyskinesia in patients with Parkinson's disease. AMPA receptor antagonists have previously been shown to have both anti-parkinsonian and anti-dyskinetic actions in MPTP-lesioned primates, suggesting that AMPA receptor transmission is functionally overactive under these conditions. In this study, we investigated the level of striatal AMPA receptor binding in the MPTP lesioned primate using the selective AMPA ligand ³H-(S)-5-fluorowillardiine. AMPA receptor binding was studied in nonparkinsonian, nondyskinetic parkinsonian, and dyskinetic macaques. Striatal AMPA receptor binding was not different in any of the treatment groups (P > 0.05). Although AMPA receptor-mediated transmission is functionally overactive in Parkinson's disease and dyskinesia, changes in striatal AMPA receptor levels are not likely to be the cause of such movement disorders. ©2002 Elsevier Science (USA).

Keywords: Parkinson'; s disease; glutamate; AMPA; MPTP; primate; binding; dyskinesia

Language: English

Document Type: Research article

Affiliations: Manchester Movement Disorders Laboratory, Manchester, United Kingdom

Publication date: 2002-03-01